نتائج البحث

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

• Authors : National Cancer Institute (NCI)

• Source: Phase II Study of Adding the Anti-PD-1 Pembrolizumab to Tyrosine Kinase Inhibitors in Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease

تفاصيل العنوان

Asciminib add-on to imatinib demonstrates sustained high rates of ongoing therapy and deep molecular responses with prolonged follow-up in the ASC4MORE study.

• Authors : Hughes, Timothy P.¹ (AUTHOR) ; Saglio, Giuseppe² (AUTHOR); Geissler, Jan³ (AUTHOR)

• Source: Journal of Hematology & Oncology. 12/18/2024, Vol. 17 Issue 1, p1-12. 12p.

تفاصيل العنوان

Overcoming the imatinib-resistant BCR-ABL mutants with new ureidobenzothiazole chemotypes endowed with potent and broad-spectrum anticancer activity.

• Authors : El-Damasy, Ashraf K.^1,2 (AUTHOR) ; Jin, Heewon¹ (AUTHOR); Park, Jung Woo³ (AUTHOR)

Subjects: *NILOTINIB; *ANTINEOPLASTIC agents; *CHRONIC myeloid leukemia

• Source: Journal of Enzyme Inhibition & Medicinal Chemistry. Dec2023, Vol. 38 Issue 1, p1-9. 9p.

تفاصيل العنوان

Asciminib, a novel allosteric inhibitor of BCR‐ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance.

• Authors : Okamoto, Naoki^1,2; Yagi, Kenta^1,3 ; Imawaka, Sayaka¹

• Source: Pharmacology Research & Perspectives. Aug2024, Vol. 12 Issue 4, p1-9. 9p.

تفاصيل العنوان

Study of Efficacy and Safety of Asciminib in Combination With Imatinib in Patients With Chronic Myeloid Leukemia in Chronic Phase (CML-CP)

• Source: A Phase 2, Multi-center, Open-label, Randomized Study of Oral Asciminib Added to Imatinib Versus Continued Imatinib Versus Switch to

تفاصيل العنوان

Physiologically based pharmacokinetic modeling of imatinib and N‐desmethyl imatinib for drug–drug interaction predictions.

• Authors : Loer, Helena Leonie Hanae¹ (AUTHOR); Kovar, Christina^1,2 (AUTHOR); Rüdesheim, Simeon^1,2 (AUTHOR)

• Source: CPT: Pharmacometrics & Systems Pharmacology. Jun2024, Vol. 13 Issue 6, p926-940. 15p.

تفاصيل العنوان

Clinical efficacy and safety of first‐line nilotinib or imatinib therapy in patients with chronic myeloid leukemia—Nationwide real life data.

• Authors : Belohlavkova, Petra¹ (AUTHOR) ; Zackova, Daniela² (AUTHOR); Klamova, Hana³ (AUTHOR)

• Source: Cancer Medicine. Sep2024, Vol. 13 Issue 17, p1-10. 10p.

تفاصيل العنوان

Sensitive adsorptive stripping voltammetric procedure of Imatinib determination in spiked urine samples using solid lead microelectrode.

• Authors : Gęca, Iwona¹ (AUTHOR) ; Korolczuk, Mieczyslaw¹ (AUTHOR)

• Source: Electroanalysis. Jul2023, Vol. 35 Issue 7, p1-8. 8p.

تفاصيل العنوان

Gynecomastia in a Chronic Myeloid Leukemia Patient After Switching from Imatinib to Flumatinib.

• Authors : Luan, Chengxin (AUTHOR); Zhu, Ying (AUTHOR); Zhao, Hongguo (AUTHOR)

• Source: Patient Preference & Adherence. Sep2024, Vol. 18, p1961-1964. 4p.

تفاصيل العنوان

From Personalized to Precision Medicine in Oncology: A Model-Based Dosing Approach to Optimize Achievement of Imatinib Target Exposure.

• Authors : Goutelle, Sylvain^1,2,3 (AUTHOR) ; Guidi, Monia^4,5,6 (AUTHOR) ; Gotta, Verena⁷ (AUTHOR)

• Source: Pharmaceutics. Apr2023, Vol. 15 Issue 4, p1081. 17p.

تفاصيل العنوان